Clinical Trial: NCT06671379
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Information Provided By: | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Last Update Posted: | 2026-03-19 |
Study Overview
Brief Summary
This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.
Official Title
A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: SHR-A2009 monotherapy
- Drug: platinum-based dual-agent chemotherapy
Other Study ID Numbers
- SHR-A2009-301
Start Date (Actual)
2024-11-29
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2027-06
Enrollment (Actual)
498
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Information Provided By: | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Last Update Posted: | 2026-03-19 |
Study Overview
Brief Summary
This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.
Official Title
A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: SHR-A2009 monotherapy
- Drug: platinum-based dual-agent chemotherapy
Other Study ID Numbers
- SHR-A2009-301
Start Date (Actual)
2024-11-29
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2027-06
Enrollment (Actual)
498
Study Type
Interventional
Phase
Phase 3